Definitely a bummer. I was really hoping ENTA would be able to have two-thirds of a possible functional cure for HBV. It is still early on and if they have other options in the pipeline they could hopefully get it going more quickly given this recent discontinuation. The safety issue must have been very obvious, consistent, and/or severe given the quick hook they gave it. Hopefully it isn't a class effect if they have another RNA destabilizer in the pipeline.
News 
Market Data 
Discover 
